Published in Br Med J on November 04, 1978
Polymorphic metabolism of beta-adrenoceptor antagonists. Br J Clin Pharmacol (1984) 1.08
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol (1982) 0.91
Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum (2003) 2.51
Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet (1985) 1.70
Drug-drug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol (1999) 1.63
Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol (1996) 1.50
Persistence of sisomicin and gentamicin in renal cortex and medulla compared with other organs and serum of rats. Kidney Int (1976) 1.48
Elective ventilation of potential organ donors. BMJ (1995) 1.45
Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther (1980) 1.44
Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs. Br J Obstet Gynaecol (1984) 1.35
Central analgesic effect of acetaminophen but not of aspirin. Clin Pharmacol Ther (1991) 1.30
Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res (1998) 1.29
Renal failure, drug pharmacokinetics and drug action. Clin Pharmacokinet (1976) 1.29
Distribution and excretion of doxycycline in man. Chemotherapy (1966) 1.26
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol (1986) 1.23
The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J (2008) 1.23
Renal transplantation in the rat: details of a technique. Aust N Z J Surg (1971) 1.23
A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther (1998) 1.21
Organ donation in the UK: a survey by a British Transplantation Society working party. Nephrol Dial Transplant (1997) 1.21
[Pharmacokinetics of a new cephalosporin, cefoperazone]. Schweiz Med Wochenschr (1979) 1.20
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sci (1993) 1.14
The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica (1986) 1.14
[Prognosis and development of myocardial infarct]. Schweiz Med Wochenschr (1965) 1.13
Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther (1985) 1.12
[Complex pneumoconiosis in dental laboratory technicians]. Poumon Coeur (1978) 1.11
Kinetics of blood component adsorption on poly(D,L-lactic acid) nanoparticles: evidence of complement C3 component involvement. J Biomed Mater Res (1997) 1.09
An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics (1998) 1.09
Pharmacokinetics of ampicillin, cephalothin and doxycycline in various tissues of the rat. Chemotherapy (1977) 1.08
Reduction of fat accumulation and lipid disorders by individualized light aerobic training in human immunodeficiency virus infected patients with lipodystrophy and/or dyslipidemia. Diabetes Metab (2002) 1.07
Diet and opiate addiction: a quantitative assessment of the diet of non-institutionalized opiate addicts. Br J Addict (1989) 1.07
The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol (2010) 1.06
Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. Pharm Acta Helv (1998) 1.06
Treatment of acute neonatal vascular injuries--the utility of multiple interventions. J Pediatr Surg (1999) 1.05
In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol (1996) 1.05
A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther (1999) 1.05
Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol (1991) 1.05
The kidney in maturity onset diabetes mellitus: a clinical study of 510 patients. Kidney Int (1982) 1.04
Management of sudden psychiatric disorders related to efavirenz. AIDS (2001) 1.04
Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer (2000) 1.03
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther (1998) 1.03
High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res (2000) 1.03
[Kinetics of tetracyclines in human. II. Excretion, penetration into normal and inflammed tissues, behavior in a case of renal insufficiency and in hemodialysis]. Schweiz Med Wochenschr (1971) 1.01
[Tetracycline kinetics in man. Digestive absorption and serum concentration]. Schweiz Med Wochenschr (1971) 1.01
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther (1995) 0.99
Lack of acetaminophen ceiling effect on R-III nociceptive flexion reflex. Eur J Clin Pharmacol (1998) 0.99
The genetic control of bufuralol metabolism in man. Eur J Drug Metab Pharmacokinet (1982) 0.99
Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br J Cancer (1990) 0.97
A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res (1993) 0.96
Adrenergic modification of glucose-induced biphasic insulin release from perifused rat pancreas. Eur J Clin Invest (1971) 0.96
Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyngeal cancers. Int J Cancer (1999) 0.95
The healing of chronic venous leg ulcers with prepared human amnion. Br J Plast Surg (1989) 0.94
Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol Suppl (2003) 0.94
The influence of patient and physician gender on prescription of psychotropic drugs. J Clin Epidemiol (1992) 0.93
Stereoselective interaction between piroxicam and acenocoumarol. Br J Clin Pharmacol (1996) 0.93
Dynamic aspects of proinsulin release from perifused rat pancreas. Lancet (1969) 0.92
Accidental bromine exposure in an urban population: an acute epidemiological assessment. Int J Epidemiol (1988) 0.92
Passive enhancement of kidney allografts: potentiation with antithymocyte serum. Transplantation (1972) 0.92
Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation. FEBS Lett (1984) 0.92
Defective hydroxylation of bufuralol associated with side-effects of the drug in poor metabolisers. Br J Clin Pharmacol (1982) 0.91
Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol (1975) 0.91
Perifusion of rat pancreatic tissue in vitro: substrate modification of theophylline-induced biphasic insulin release. J Clin Invest (1970) 0.91
Salivary electrolytes and digitalis. Eur Heart J (1983) 0.91
N-acetyltransferase NAT1 and NAT2 genotypes and lung cancer risk. Pharmacogenetics (1998) 0.90
Behaviour of doxycycline in renal insuffciency. Helv Med Acta (1969) 0.90
In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol (1991) 0.90
Liver and bone marrow granulomas in Q fever. Gastroenterology (1983) 0.89
Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer (2001) 0.89
[Pharmacokinetics of two beta blocking drugs: detection of a pharmacogenetic abnormality]. Schweiz Med Wochenschr (1976) 0.89
Results of heart-lung transplantation in children with cystic fibrosis. Eur J Cardiothorac Surg (1995) 0.89
Concentrations of azithromycin in tonsilar and/or adenoid tissue from paediatric patients. J Antimicrob Chemother (1996) 0.89
Effects of beta-blockade on energy metabolism following burns. Burns (1990) 0.88
Chasing, arousal and sensation seeking in off-course gamblers. Br J Addict (1987) 0.88
Urinary protein analysis with sodium dodecylsulfate polyacrylamide gel electrophoresis: a comparison with other analytical techniques. Clin Chim Acta (1974) 0.88
Role of glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes in modulating susceptibility to smoking-related lung cancer. Pharmacogenetics (1998) 0.87
Pharmacokinetic-pharmacodynamic modeling of the effects of clonidine on pain threshold, blood pressure, and salivary flow. Eur J Clin Pharmacol (1992) 0.87
Simultaneous tubular excretion and reabsorption of pindolol in man. Eur J Clin Pharmacol (1981) 0.87
[Duality of the analgesic effect of tramadol in humans]. Schweiz Med Wochenschr (1993) 0.86
Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol (1977) 0.86
Recurrent renal salt wasting in a child treated with carboplatin and etoposide. Cancer (1994) 0.85
Recent drug management advances in renal insufficiency. Adv Nephrol Necker Hosp (1974) 0.85
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents. Clin Pharmacokinet (1980) 0.85
Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. Cancer Epidemiol Biomarkers Prev (1998) 0.85